Hyaluronic Acid is Associated with Severity and Prognosis in Patients with Community-Acquired Pneumonia

Overview

Journal J Inflamm Res

Publisher Dove Medical Press

Date 2025 Jan 13

PMID 39802154

Authors

Yingying Lin

Yanyan Li

Xinyu Cui

Na Zhu

Xin Li

Affiliations

Soon will be listed here.

Abstract

Purpose: Hyaluronic acid (HA) is a novel inflammatory biomarker with a prognostic value for several infectious diseases. This study investigated the association of HA with severity and prognosis in hospitalized patients with community-acquired pneumonia (CAP).

Patients And Methods: We analyzed the differences of HA levels in different groups. Logistic regression analysis was performed to identify independent risk factors for severe CAP (SCAP). The predictive value of HA for SCAP was assessed using receiver operating characteristic (ROC) curves. Kaplan-Meier survival analysis was used to compare 30-day mortality between the high and low HA groups.

Results: Compared to healthy controls (49.2 ± 15.3 ng/mL), patients with CAP exhibited significantly elevated levels of HA (P < 0.001). In CAP patients, increased HA levels were more pronounced in those with SCAP (SCAP vs non-SCAP:135.6 ± 51 ng/mL vs 100.7 ± 47.8 ng/mL, P < 0.001). Compared to survivors (109.9 ± 48.7 ng/mL), HA levels in non-survivors were significantly higher (180.9 ± 67.8 ng/mL) (P < 0.001). HA was an independent predictor of SCAP [odds ratio (OR): 1.013, 95% confidence interval (CI): 1.003-1.022, P = 0.011] with high diagnostic accuracy [areas under the curve (AUC): 0.709, 95% CI: 0.622-0.797, P = 0.001]. Additionally, HA was independently associated with death risk in patients with CAP (OR: 1.022, 95% CI: 1.005-1.039, P = 0.010). Kaplan-Meier survival curves indicated that CAP patients in the high HA group exhibit a higher 30-day mortality rate compared to those in the low HA group (8.6% vs 1.5%, P = 0.008). Post hoc analysis indicated that our study possessed 98.857% statistical power.

Conclusion: In conclusion, High HA levels are associated with severity and mortality in patients with CAP, and HA could serve as a novel serum biomarker to predict the risk of CAP progression.

Citing Articles

Could the Systemic Inflammatory Response Index be a Marker for the Non-Dipper Pattern in Newly Diagnosed Hypertensive Patients?.

Kaplangoray M, Toprak K, Caglayan C, Deveci E, Celik E, Uyan U Cardiovasc Toxicol. 2025; 25(4):559-569.

PMID: 39992556 DOI: 10.1007/s12012-025-09977-3.

References

Phua J, Dean N, Guo Q, Kuan W, Lim H, Lim T . Severe community-acquired pneumonia: timely management measures in the first 24 hours. Crit Care. 2016; 20:237. PMC: 5002335. DOI: 10.1186/s13054-016-1414-2. View

Jain S, Self W, Wunderink R, Fakhran S, Balk R, Bramley A . Community-Acquired Pneumonia Requiring Hospitalization among U.S. Adults. N Engl J Med. 2015; 373(5):415-27. PMC: 4728150. DOI: 10.1056/NEJMoa1500245. View

Fine M, Auble T, Yealy D, Hanusa B, Weissfeld L, Singer D . A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 1997; 336(4):243-50. DOI: 10.1056/NEJM199701233360402. View

Uchimido R, Schmidt E, Shapiro N . The glycocalyx: a novel diagnostic and therapeutic target in sepsis. Crit Care. 2019; 23(1):16. PMC: 6337861. DOI: 10.1186/s13054-018-2292-6. View

Richardson S, Schairer W, Sculco T, Sculco P . Comparison of Infection Risk with Corticosteroid or Hyaluronic Acid Injection Prior to Total Knee Arthroplasty. J Bone Joint Surg Am. 2019; 101(2):112-118. DOI: 10.2106/JBJS.18.00454. View

Xu Z, Wang X, Cao P, Zhang C, Feng C, Zheng L . Serum IL-27 predicts the severity and prognosis in patients with community-acquired pneumonia: a prospective cohort study. Int J Med Sci. 2022; 19(1):74-81. PMC: 8692123. DOI: 10.7150/ijms.67028. View

Su Y, Gu H, Weng D, Zhou Y, Li Q, Zhang F . Association of serum levels of laminin, type IV collagen, procollagen III N-terminal peptide, and hyaluronic acid with the progression of interstitial lung disease. Medicine (Baltimore). 2017; 96(18):e6617. PMC: 5419904. DOI: 10.1097/MD.0000000000006617. View

Pettigrew M, Tanner W, Harris A . The Lung Microbiome and Pneumonia. J Infect Dis. 2020; 223(12 Suppl 2):S241-S245. DOI: 10.1093/infdis/jiaa702. View

Feng C, Wang X, Li M, Xu Z, Hua D, Cheng J . Serum interleukin-17 predicts severity and prognosis in patients with community acquired pneumonia: a prospective cohort study. BMC Pulm Med. 2021; 21(1):393. PMC: 8637026. DOI: 10.1186/s12890-021-01770-6. View

10.

Yang T, Zhang L, Sun S, Yao X, Wang L, Ge Y . Identifying severe community-acquired pneumonia using radiomics and clinical data: a machine learning approach. Sci Rep. 2024; 14(1):21884. PMC: 11413163. DOI: 10.1038/s41598-024-72310-5. View

11.

Huang X, Lu F, Tian H, Hu H, Ning F, Shang Q . Association between plasma glycocalyx component levels and poor prognosis in severe influenza type A (H1N1). Sci Rep. 2022; 12(1):163. PMC: 8741814. DOI: 10.1038/s41598-021-04146-2. View

12.

Martin-Loeches I, Nagavci B, Torres A . Guidelines for the management of severe community-acquired pneumonia: one confusing recommendation. Author's reply. Intensive Care Med. 2023; 49(10):1261-1262. DOI: 10.1007/s00134-023-07184-8. View

13.

Theocharis A, Manou D, Karamanos N . The extracellular matrix as a multitasking player in disease. FEBS J. 2019; 286(15):2830-2869. DOI: 10.1111/febs.14818. View

14.

Li M, Chen Y, Li H, Yang D, Zhou Y, Chen Z . Serum CXCL10/IP-10 may be a potential biomarker for severe Mycoplasma pneumoniae pneumonia in children. BMC Infect Dis. 2021; 21(1):909. PMC: 8418284. DOI: 10.1186/s12879-021-06632-4. View

15.

Esposito S, Bianchini S, Gambino M, Madini B, Di Pietro G, Umbrello G . Measurement of lipocalin-2 and syndecan-4 levels to differentiate bacterial from viral infection in children with community-acquired pneumonia. BMC Pulm Med. 2016; 16(1):103. PMC: 4955239. DOI: 10.1186/s12890-016-0267-4. View

16.

Liu Y, Zhang Y, Xu Q, Qiu Y, Lu Q, Wang T . Infection and co-infection patterns of community-acquired pneumonia in patients of different ages in China from 2009 to 2020: a national surveillance study. Lancet Microbe. 2023; 4(5):e330-e339. DOI: 10.1016/S2666-5247(23)00031-9. View

17.

Woodhead M, Welch C, Harrison D, Bellingan G, Ayres J . Community-acquired pneumonia on the intensive care unit: secondary analysis of 17,869 cases in the ICNARC Case Mix Programme Database. Crit Care. 2006; 10 Suppl 2:S1. PMC: 3226135. DOI: 10.1186/cc4927. View

18.

Yang S, Ling Y, Zhao F, Li W, Song Z, Wang L . Hymecromone: a clinical prescription hyaluronan inhibitor for efficiently blocking COVID-19 progression. Signal Transduct Target Ther. 2022; 7(1):91. PMC: 8931182. DOI: 10.1038/s41392-022-00952-w. View

19.

Schmidt E, Overdier K, Sun X, Lin L, Liu X, Yang Y . Urinary Glycosaminoglycans Predict Outcomes in Septic Shock and Acute Respiratory Distress Syndrome. Am J Respir Crit Care Med. 2016; 194(4):439-49. PMC: 5003330. DOI: 10.1164/rccm.201511-2281OC. View

20.

Jiang D, Liang J, Fan J, Yu S, Chen S, Luo Y . Regulation of lung injury and repair by Toll-like receptors and hyaluronan. Nat Med. 2005; 11(11):1173-9. DOI: 10.1038/nm1315. View